Safety and Effectiveness Study of OR3O™ Dual Mobility System in THA

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

177 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-27

Study Completion Date

2035-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and effectiveness of the OR3O™ Dual Mobility System. The study will evaluate the outcome of the Total Hip Arthroplasty using the OR3O™ Dual Mobility System over a ten year period. Survivorship of THA will be assessed up to ten years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety and Efficacy of OR3O™ Dual Mobility System vs. Conventional Single Bearing Design Total Hip System

NCT04941729

Degenerative Hip Joint Disease Rheumatoid Arthritis (RA) Femoral Neck Fractures +4 more

TERMINATED NA

THA Kinematics and Sound for Subjects for Normal, Diseased and Implanted Hips

NCT02682602

Hip Injuries

COMPLETED

A Multi-centre Study to Assess the Long-term Performance of the Summit™ Hip in Primary Total Hip Replacement

NCT00208390

Rheumatoid Arthritis Osteoarthritis Post-traumatic Arthritis +6 more

TERMINATED PHASE4

Observational Study Evaluating Outcomes of Hip Arthroplasty Using Tornier Dual Mobility Acetabular Cup

NCT02062450

Primary Osteoarthritis Post-traumatic Osteoarthritis of Hip Nos Femur Head Necrosis +2 more

COMPLETED

EU Safety and Efficacy Study Regarding the R3 Acetabular Hip System

NCT04399928

Degenerative Joint Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Degeneration of the Hip Joint Revision of the Hip Joint

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary Total Hip Arthroplasty (THA)

OR3O Dual Mobility System used in primary THA

Primary Total Hip Arthroplasty

Intervention Type DEVICE

Primary Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components

Revision Total Hip Arthroplasty (THA)

OR3O Dual Mobility System used in revision THA

Revision Total Hip Arthroplasty

Intervention Type DEVICE

Revision Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Primary Total Hip Arthroplasty

Primary Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components

Intervention Type DEVICE

Revision Total Hip Arthroplasty

Revision Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All subjects:

* Subject is a suitable candidate for implanting the OR3O™ Dual Mobility System in primary or revision total hip replacement in the Investigator's judgement.
* Subject is skeletally mature in the Investigator's judgement.
* Subject is 18 - 80 years old (inclusive).
* Subject has any of the following conditions:

* Advanced degeneration of the hip joint as a result of degenerative, post-traumatic, or rheumatoid arthritis (RA);
* Fracture or avascular necrosis of the femoral head;
* Failure of previous hip surgery: joint reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip replacement;
* All forms of osteoarthritis (OA);
* Patients with hips at risk of dislocation;
* Femoral neck fracture or proximal hip joint fracture.
* Subject provides written informed consent for study participation using an Independent Ethical Committee (IEC) / Institutional Review Board (IRB) approved consent form before any study procedures are performed, including pre-operative data review and/or collection of data on electronic Case Report Forms (eCRFs).
* Subject is willing and able to participate in required follow-up visits and is able to complete study activities.
* Subject has all required study pre-operative and operative data available in their medical record for collection if consent is given after their THA surgery.

Revision Subjects:

* Subject has a REDAPT™ Modular Shell implanted which does not require revision or will receive a REDAPT™ Modular Shell during revision THA.
* Subject has a S+N compatible stem which does not require revision or will receive a S+N compatible stem during revision THA.

Exclusion Criteria

All subjects:

* Subject has conditions that would eliminate or tend to eliminate adequate implant support or prevent the use of an appropriately-sized implant, e.g.:

* blood supply limitations;
* insufficient quantity or quality of bone support, e.g., osteoporosis, metabolic disorders which may impair bone formation, radioactive bone disease, tumor around hip joint, and osteomalacia;
* infections or other conditions which may lead to increased bone resorption.
* Subject has dysplasia of hip joint with CROWE Grade III, IV.
* Subject has bodily disease(s) that may interfere with THA survival or outcome.
* Subject has life expectancy of less than 10 years.
* Subject has mental or neurological conditions which impair the subject's ability or willingness to restrict activities that may put the affected limb at risk.
* Subject has physical conditions or activities which tend to place extreme loads on implants, e.g., Charcot joints, muscle deficiencies, multiple joint disabilities.
* Subject has neuromuscular dysfunctions (paralysis, myolysis and abductor muscle weakness) which will cause unstable hip joint or abnormal gait after surgery.
* Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study.
* Subject has an active infection - systemic or at the site of intended surgery.
* Subject has a Body Mass Index \> 40.0 kg/m².
* Subject has a known allergy to any component of the devices used in the study.
* Subject is pregnant or breast feeding.
* Subject is entered in another investigational drug, biologic, or device study within 30 days of active study participation.

Revision Subjects:

* Subject has inadequate implant support with an increased risk of implant failure if support is not achieved, poor bone quality exists, or smaller sized implants are utilized.
* Subject needs revision of a fractured ceramic head or liner.
* Subject was already enrolled into this study as primary THA case.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No